Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

Recent biomarker analyses from our initial mouse DIO study have further extended ... CB1 inhibitor and the dual GLP-1 GIP agonist tirzepatide both alone and in combination with Nimacimab using ...

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide ... Enhanced safety: Diet-induced obesity ("DIO”) mouse model data highlighted the sufficiency of the ...

Nimacimab in combination with tirzepatide improves weight loss ... Enhanced safety: Diet-induced obesity (“DIO”) mouse model data highlighted the sufficiency of the highly-peripherally ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

There are improved all-cause mortality, rhythm control, and adverse cardiac event outcomes in patients being treated with tirzepatide who have atrial fibrillation. Patients with atrial ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...